SCHEMBL330598

SCHEMBL330598

Nc1nc(Cc2ccccc2)c(-c2ccccc2)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.56
MAPT P10636 5/20 0.56
CYP1A2 P05177 4/20 0.56
CYP2D6 P10635 3/20 0.56
CYP2C19 P33261 3/20 0.56
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
KDM4E B2RXH2 2/20 0.50
GAA P10253 2/20 0.50
LTA4H P09960 1/20 0.45
LTB4R Q15722 2/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PKM P14618 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL330140 0.81 ALDH1A1 (0.58) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL27704531 0.81 ALDH1A1 (0.58) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL10242382 0.79 ALOX5 (0.54) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL22588269 0.77 ALDH1A1 (0.47) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL27626590 0.77 CYP1A2 (0.59) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL11838323 0.77 ALDH1A1 (0.53) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL20832524 0.77 ALDH1A1 (0.53) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL331680 0.76 ALDH1A1 (0.51) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL27664851 0.76 ALDH1A1 (0.48) ALDH1A1MAPTKDM4EGAAMEN1
Bromide SCHEMBL28889091 0.76 CYP1A2 (0.57) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115515685-B EIF4E inhibitors and uses thereof 皮克医疗公司 2025-04-08 CN disclosed
US-12157731-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2024-12-03 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
EP-4114529-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2023-01-11 EP disclosed
US-20220356178-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2022-11-10 US disclosed
EP-1555018-A1 REMEDIES FOR NEURODEGENERATIVE DISEASES Institute of Medicinal Molecular Design, Inc. (JP) 2005-07-20 EP disclosed
EP-1535609-A1 NF-KB ACTIVATION INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-06-01 EP disclosed
EP-1535610-A1 THERAPEUTIC AGENT FOR CANCER Institute of Medicinal Molecular Design, Inc. (JP) 2005-06-01 EP disclosed
EP-1514544-A1 ANTIALLERGIC Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-16 EP disclosed
EP-1512396-A1 INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-09 EP disclosed
EP-1510210-A1 IMMUNITY-RELATED PROTEIN KINASE INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 EP disclosed
EP-1510207-A1 THERAPEUTIC DRUG FOR DIABETES Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 US disclosed
CN-1489458-A Inflammatory cytokine production dissociation inhibitor ��ʽ����ҽҩ��������о��� 2004-04-14 CN disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885MAPT 2231/4885CYP1A2 4834/4885
US-12157731-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885MAPT 2231/4885CYP1A2 4834/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885MAPT 2231/4885CYP1A2 4834/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB ALDH1A1 1025/4885MAPT 2435/4885CYP1A2 1483/4885
US-20220356178-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885MAPT 2231/4885CYP1A2 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.